Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT02495896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as recombinant EphB4-HSA fusion protein, paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, docetaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether standard chemotherapy regimens are more effective with recombinant ephB4-HSA fusion protein in treating advanced or metastatic solid tumors.
Study identification
- NCT ID
- NCT02495896
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 61 participants
Conditions and interventions
Conditions
- Head and Neck Squamous Cell Carcinoma
- Metastatic Pancreatic Adenocarcinoma
- Non-Resectable Cholangiocarcinoma
- Pancreatic Adenocarcinoma
- Recurrent Gallbladder Carcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- Stage III Pancreatic Cancer
- Stage IIIA Gallbladder Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Gallbladder Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Gallbladder Cancer
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Pancreatic Cancer
- Unresectable Gallbladder Carcinoma
- Unresectable Pancreatic Cancer
Interventions
- Cisplatin Drug
- Docetaxel Drug
- Gemcitabine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation Drug
- Pharmacological Study Other
- Recombinant EphB4-HSA Fusion Protein Biological
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2, 2015
- Primary completion
- Mar 31, 2021
- Completion
- Dec 30, 2026
- Last update posted
- Apr 28, 2026
2015 – 2026
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02495896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02495896 live on ClinicalTrials.gov.